Forte Biosciences, Inc.

Quick facts

Phase 2 pipeline

• FB102 · Diabetes
  FB102 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Forte Biosciences, Inc. portfolio CI brief
• Forte Biosciences, Inc. pipeline updates RSS